Pulmonary Arterial Hypertension Pipeline Summary

DelveInsight’s, “Pulmonary Arterial Hypertension - Pipeline Insight, 2026” report provides comprehensive insights about 58+ companies and 60+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pulmonary Arterial Hypertension: Understanding

Pulmonary Arterial Hypertension: Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease characterized by increased pressure in the pulmonary arteries and progressive remodeling and narrowing of the small pulmonary arteries. This results in increased pulmonary vascular resistance and progressive elevation of pulmonary arterial pressure, placing an increasing pressure load on the right ventricle. If untreated, the disease can progress to right ventricular failure and death. Common clinical manifestations include dyspnea, fatigue, chest pain, and syncope.

PAH can occur as idiopathic or heritable disease or can develop in association with several underlying conditions and exposures. Important associated causes include connective tissue diseases, congenital heart disease, HIV infection, portal hypertension, and exposure to certain drugs or toxins. Heritable PAH is frequently associated with mutations in the BMPR2 gene, which plays an important role in pulmonary vascular homeostasis.

The pathophysiology of PAH involves complex abnormalities in the pulmonary vasculature, including vasoconstriction, vascular cell proliferation, inflammation, thrombosis, and progressive structural remodeling. The characteristic pathological changes include medial hypertrophy, fibrotic intimal proliferation, and perivascular inflammatory infiltration, resulting in loss and narrowing of pulmonary resistance vessels. Endothelial dysfunction leads to an imbalance among major vasoactive pathways, particularly increased endothelin signaling and reduced nitric oxide and prostacyclin activity. Genetic abnormalities, particularly alterations in the BMPR2/TGF-? signaling pathway, also contribute to pulmonary vascular remodeling and disease progression.

Diagnosis of PAH requires a systematic evaluation to confirm pulmonary hypertension, establish its underlying cause, and distinguish PAH from other forms of pulmonary hypertension. Initial assessment may include clinical history and examination, electrocardiography, blood tests, pulmonary function testing, and imaging such as echocardiography. Right heart catheterization performed in an experienced specialized center is essential for definitive diagnosis and hemodynamic assessment. Pre-capillary pulmonary hypertension is characterized by a mean pulmonary artery pressure above 20 mmHg, pulmonary artery wedge pressure of 15 mmHg or less, and elevated pulmonary vascular resistance.

Treatment of PAH aims to reduce pulmonary vascular resistance, improve symptoms and functional capacity, delay disease progression, and achieve a low-risk clinical status.

Management includes general and supportive measures together with PAH-specific therapies targeting three major endothelial pathways: the endothelin pathway using endothelin receptor antagonists, the nitric oxide–cyclic GMP pathway using phosphodiesterase-5 inhibitors or soluble guanylate cyclase stimulators, and the prostacyclin pathway using prostacyclin analogues or prostacyclin-receptor agonists. Current treatment strategies use multiparametric risk assessment to guide initial combination therapy and treatment escalation. Patients with severe disease that remains refractory despite maximal medical therapy may be considered for lung transplantation. Emerging therapies are also being investigated against pathways involved in vascular remodeling, including TGF-? and PDGF signaling.

"Pulmonary Arterial Hypertension- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension Emerging Drugs Chapters

This segment of the Pulmonary Arterial Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Arterial Hypertension Emerging Drugs

• Seralutinib: Gossamer Bio

Seralutinib is an investigational, inhaled small-molecule tyrosine kinase inhibitor developed by Gossamer Bio for the potential treatment of pulmonary arterial hypertension (PAH). It is designed to inhibit platelet-derived growth factor receptors (PDGFR?/?), colony-stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor (c-KIT), which are involved in pathways underlying pulmonary vascular remodeling. By blocking these targets, seralutinib is designed to reduce inflammation, proliferation, and fibrosis, potentially slowing or reversing the pathological vascular remodeling associated with PAH. The drug is formulated for delivery directly to the lungs through a dry powder inhaler, with the aim of reaching the site of disease. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

• CS1: Cereno Scientific AB

CS1 is a lead clinical-stage drug candidate being developed as an oral, once-daily treatment for pulmonary arterial hypertension (PAH). CS1 is a histone deacetylase (HDAC) inhibitor based on a proprietary controlled-release formulation of valproic acid (VPA). Through epigenetic modulation and HDAC inhibition, CS1 is designed to influence multiple disease-driving processes involved in PAH, including pathological vascular remodeling, fibrosis, inflammation, pulmonary arterial pressure, and thrombotic mechanisms. Cereno Scientific states that this multimodal mechanism has the potential to reverse pathological vascular remodeling and thereby slow, halt, or reverse PAH disease progression. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Pulmonary Arterial Hypertension.

• DIAG723: Diagonal Therapeutics

DIAG723 is an investigational first-in-class bispecific clustering antibody designed to address dysregulated ALK1 signaling, which contributes to vascular hyperproliferation in PAH. DIAG723 works by clustering the ALK1 and BMPRII receptors to stimulate antiproliferative signaling and restore signaling lost due to impaired receptor function. By restoring ALK1 signaling, DIAG723 is designed to prevent pulmonary vascular hyperproliferation and cardiac remodeling, with preclinical studies demonstrating improved hemodynamics and prevention of PAH development. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Pulmonary Arterial Hypertension.

• GSK6792070 : GSK

GSK6792070 (HS235) is an investigational activin signaling inhibitor being developed by GSK for pulmonary arterial hypertension (PAH). It targets the activin receptor signaling pathway, a clinically validated therapeutic target in pulmonary hypertension. HS235 is designed with enhanced selectivity by reducing binding to BMP9 and BMP10, which are associated with adverse events such as bleeding and telangiectasia. Through its activin signaling inhibition and selective profile, HS235 is intended to potentially reduce the risk of bleeding while providing potential protective effects on vascular function. GSK also states that its underlying mechanism may provide metabolic benefits, including fat-selective weight loss, preservation of lean mass, and improved insulin sensitivity. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Pulmonary Arterial Hypertension.

• CM5480: CalciMedica

CM5480 is oral CRAC channel inhibitor being developed as a potential treatment for pulmonary arterial hypertension (PAH). CM5480 selectively and potently inhibits calcium release-activated calcium (CRAC) channels, of which Orai1 is the pore-forming subunit, thereby controlling the entry of calcium ions into cells. CalciMedica states that inhibition of Orai1-containing CRAC channels may regulate abnormal calcium entry linked to vasoconstriction, pulmonary vascular remodeling, and right ventricular dysfunction. In preclinical PAH models, CM5480 improved pulmonary hemodynamics and reduced pulmonary vascular and right ventricular remodeling, both as monotherapy and in combination with vasodilators. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Pulmonary Arterial Hypertension.

Further product details are provided in the report……..

Pulmonary Arterial Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pulmonary Arterial Hypertension

There are approx. 58+ key companies which are developing the therapies Pulmonary Arterial Hypertension. The companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Phase III include, Gossamer Bio and others.

• Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Arterial Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension drugs.

Pulmonary Arterial Hypertension Report Insights

• Pulmonary Arterial Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pulmonary Arterial Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pulmonary Arterial Hypertension drugs?
• How many Pulmonary Arterial Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gossamer Bio
• Cereno Scientific AB
• Diagonal Therapeutics
• CalciMedica
• Pfizer
• United Therapeutics Corporation
• GSK
• Gmax Biopharm
• Apollo Therapeutics Ltd
• Regeneron Pharmaceuticals
• Guangzhou Magpie Pharmaceuticals Co., Ltd.
• Allrock Bio
• ImmuneOnco Biopharmaceuticals
• Tectonic Therapeutics
• Roivant Sciences

Key Products

• Seralutinib
• CS1
• DIAG723
• CM5480
• PF-07868489
• Ralinepag
• GSK6792070 (HS235)
• GMA301
• APL-9796
• REGN13335
• MN-08
• ROC-101
• IMC-003
• TX000045
• Mosliciguat